



August 26, 2024

**BSE Limited**

1<sup>st</sup> Floor, P J Towers,  
Dalal Street,  
Mumbai-400001

**Code: 532321**

**National Stock Exchange of India Limited**

Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai-400051

**Code: Zyduslife**

**Re.: News aired in Mainstream Media on August 26, 2024**

**Ref.: Disclosure under regulation 30(11) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”)**

Dear Sir / Madam,

With reference to the captioned subject, we have noted about one news on August 26, 2024, in Mainstream Media regarding increased competition for Asacol HD. We have also noted that there is a material price movement in the share price of the Company on the stock exchanges today.

Firstly, we would like to inform that the Company has given statutory intimation and press release regarding acquisition of 50% stake of Sterling Biotech Limited on August 23, 2024. We strongly believe that today’s material price movement in the shares of the Company is not attributable to this event.

Further, we have noted that an approval for the generic product in the name of gAsacol HD (Mesalamine 800 mg) of the Company, marketed in the United States of America, has been given by the USFDA to another company. This could lead to a potential competition and impact the sales and profits from the said product and the same is on anticipated lines. The impact of the same is already factored by the Company in its sales and operating profit (EBITDA) expectations for FY2025 shared in the post results investors call on August 9, 2024. The Company had guided for an improvement in consolidated EBITDA margin by about 150 basis points in

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : [www.zyduslife.com](http://www.zyduslife.com) | CIN : L24230GJ1995PLC025878





FY2025 as compared to EBITDA margin of 27.5% in FY2024 as well as high teens consolidated revenue growth and reaffirms the same.

The above may be considered as a compliance under regulation 30(11) of the Listing Regulations.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,  
For, **ZYDUS LIFESCIENCES LIMITED**

**DHAVAL N. SONI**  
**COMPANY SECRETARY**

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : [www.zyduslife.com](http://www.zyduslife.com) | CIN : L24230GJ1995PLC025878

